Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 211,135,052 papers from all fields of science
Search
Sign In
Create Free Account
CH 5132799
Known as:
CH-5132799
, CH5132799
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Pyrimidines
Sulfonamides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Melanocortin type 4 receptor–mediated inhibition of A-type K+ current enhances sensory neuronal excitability and mechanical pain sensitivity in rats
Y. Zhang
,
Dongsheng Jiang
,
+5 authors
J. Tao
Journal of Biological Chemistry
2019
Corpus ID: 73443262
α-Melanocyte–stimulating hormone (α-MSH) has been shown to be involved in nociception, but the underlying molecular mechanisms…
Expand
2015
2015
Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
Clinical Cancer Research
2015
Corpus ID: 36006376
2014
2014
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
S. Blagden
,
Aurelius Olmin
,
+16 authors
U. Banerji
Clinical Cancer Research
2014
Corpus ID: 16246505
Purpose: This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), safety…
Expand
2013
2013
P06.08FINAL RESULTS OF PHASE I STUDY OF THE ORAL CLASS I PI3K INHIBITOR CH5132799 IN PATIENTS WITH ADVANCED SOLID TUMOURS
A. Suder
2013
Corpus ID: 72712939
2012
2012
A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.
A. Omlin
,
J. Spicer
,
+17 authors
S. Blagden
2012
Corpus ID: 76213730
3022 Background: The phosphatidylinositol 3-kinase (PI3K) pathway is a promising target in cancer. CH5132799 is a novel PI3K…
Expand
Highly Cited
2011
Highly Cited
2011
The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
Hiroshi Tanaka
,
Miyuki Yoshida
,
+12 authors
Y. Aoki
Clinical Cancer Research
2011
Corpus ID: 6496099
Purpose: The phosphatidylinositol 3-kinase (PI3K) pathway plays a central role in cell proliferation and survival in human cancer…
Expand
Highly Cited
2011
Highly Cited
2011
Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799.
J. Ohwada
,
H. Ebiike
,
+11 authors
N. Shimma
Bioorganic & Medicinal Chemistry Letters
2011
Corpus ID: 8506070
2011
2011
Cancer Therapy : Preclinical The Selective Class I PI 3 K Inhibitor CH 5132799 Targets Human Cancers Harboring Oncogenic PIK 3 CA Mutations
Hiroshi Tanaka
,
Miyuki Yoshida
,
+12 authors
Y. Aoki
2011
Corpus ID: 36683305
Purpose: The phosphatidylinositol 3-kinase (PI3K) pathway plays a central role in cell proliferation and survival in human cancer…
Expand
2010
2010
122 Novel class I PI3K inhibitor CH5132799: potential clinical application in rational combination with molecular targeted therapeutics
Hiroshi Tanaka
,
Miyuki Yoshida
,
+7 authors
Y. Aoki
2010
Corpus ID: 72348171
2010
2010
74 Novel class I PI3K inhibitor CH5132799: disruption of the activated PI3K signaling in PIK3CA mutants confers potent antitumor efficacy
Miyuki Yoshida
,
Hiroshi Tanaka
,
+7 authors
Y. Aoki
2010
Corpus ID: 71656412
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE